Navigation Links
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
Date:10/2/2008

STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax Corp. (NASDAQ:DYAX) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases.

The collaboration follows the recent publication of work by Athera scientific founders, Professors Frostegard and de Faire of the Karolinska Institutet. The research links naturally occurring antibodies against phosphorylcholine (PC) to atherosclerosis, and correlates low antibody levels with an increased risk of developing cardiovascular disease. Atherosclerosis is a chronic inflammatory disease in which the walls of the blood vessels are thickened and become less elastic.

During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to generate fully human monoclonal antibodies. Athera will provide reagents, assays, and in vivo animal models for use in selecting a clinical product candidate. Upon successful completion of the discovery work, Athera and Dyax will have the option to advance the antibody lead(s) into clinical development under the terms of a global co-development and commercialization agreement.

"We are very pleased to be working with Athera," commented Clive Wood, EVP, Discovery Research and CSO of Dyax Corp. "Through their innovative research from the Karolinska Institutet, we believe Athera has identified an exciting potential opportunity for therapeutic antibody treatment of cardiovascular inflammation."

"The strength of Dyax's phage display technology, screening capabilities and expertise in drug discovery make them an excellent partner to advance our cardiovascular research program,"
'/>"/>

SOURCE Athera Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 11 Phosphagenics,Limited ("Phosphagenics") (ASX: POH; AIM: PSG; ... their joint phase 2 human clinical,trial to establish ... of metabolic syndrome is advancing at three sites ... of study participants, the,double-blind phase 2 trial, which ...
... Feb. 11 ,Pharmion (Nasdaq: PHRM ) and ... Medicines Agency (EMEA) and the European Commission (EC),designated ... Orphan,Medicinal Product for the treatment of acute myelogenous ... require that the product be,intended for the treatment ...
Cached Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:7/30/2015)... ... July 30, 2015 , ... In an effort to provide the twenty four ... a change in his practice. , The decision will also allow him to spend ... will be transferring his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... ... software, TikiLIVE, has worked to protect victims in San Diego, California’s Gaslamp Quarter ... used by Gaslamp Quarter Plaza actively monitor the area for any suspicious ...
(Date:7/30/2015)... ... ... " DevExpress ” was featured on NewsWatch as part ... large businesses making an impact in their industry. Susan Bridges, a reporter for ... how DevExpress has provided software development tools that have helped app developers build ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl Institute announces ... In partnership with Patient Experience Institute, these offerings reinforce the commitment to help ... lines and throughout the experience movement, and provide information and research to support ...
(Date:7/30/2015)... Newport Beach, California (PRWEB) , ... July 30, ... ... products and services, announced today that the latest issue of Inclusive™ magazine, its ... multiple digital platforms. The digital edition of the new issue, Volume 6, Issue ...
Breaking Medicine News(10 mins):Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
... North Carolina law firm sponsors bicycle safety video public service announcement ... ... February 17, 2009 -- HensonFuerst is giving local teens the chance ... announcement (PSA) contest in eastern North Carolina this spring. The mission ...
... CHICAGO, Feb. 17 While the common perception about ... is that it,s a rich person,s game, a Chicago ... eight years that we,ve been matching surrogates with our ... personal sacrifices. And nobody,s ever shown regret," says Robin ...
... Angeles Jewish Home are in it for the , Long ... Feb. 17 At the Los Angeles Jewish Home, one ... roof in the U.S. all agree on two things: They ... have the best ideas on just how to accomplish that ...
... Brighter smiles await,children in the Los Angeles area ... Oral Health Improvement Program to the La Canada,and Pacoima ... (Logo: http://www.newscom.com/cgi-bin/prnh/20011026/BIGLOTSLOGO ) , ... Smiles, Bright Futures dental van and its team,of dental ...
... that blocking the activity of a protein in the blood ... the study, normal mice and mice that had a genetically ... ultraviolet light that mimics chronic sun exposure. The mice that ... vascular skin cancer tumors than did the normal mice. , ...
... Michael Marmot, chair of the World Health Organization ... of the International Institute for Society and Health ... Positive Health Lecture Series talk, "Social Determinants of ... Health Lecture Series is organized by Martin Seligman, ...
Cached Medicine News:Health News:HensonFuerst Invites North Carolina Teens to Make Their Directorial Debuts 2Health News:The Surrogacy Journey: Not Just For the Wealthy 2Health News:Unique Group of 90-Year-Olds Share Top Ten Longevity Tips 2Health News:Unique Group of 90-Year-Olds Share Top Ten Longevity Tips 3Health News:Colgate's Bright Smiles, Bright Futures Program Brings Free Children's Dental Screenings to Los Angeles Area Big Lots Stores 2Health News:Blocking protein leads to fewer, smaller skin cancer tumors 2Health News:Blocking protein leads to fewer, smaller skin cancer tumors 3Health News:Blocking protein leads to fewer, smaller skin cancer tumors 4
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: